Conference Day One | Wednesday, October 16
7:50 am Check In & Morning Coffee
8:50 am Chair’s Opening Remarks
Evaluating the Current Clinical Success & Looking Toward the Future in TGF-β Targeted Therapies
9:00 am The Accomplishments of TGF-β Directed Therapies in Immuno-Oncology
Synopsis
- Navigating from preclinical to clinical trials in immuno-oncology to maintain positive patient response
- Unearthing clinical efficacy and activity of TGF-β targeted therapy to celebrate success
- Discovering the next steps in the TGF-β space for clinical triumph
New Data!
9:30 am Fireside Chat: Assessing the TGF-β Landscape & Predicting Future Innovations
Synopsis
- Exploring the current clinical successes of TGF-β targeted therapies
- Discussing the changes in the TGF-β field with the pivot to fibrosis research
- Looking to the future for developing TGF-β directed therapies and exciting new technologies using TGF-β
10:30 am Morning Break & Speed Networking
Synopsis
This networking session is your opportunity to get face-to-face with many of the brightest minds working in the TGF-β field and establish meaningful business relationships to pursue for the rest of the conference.
Utilizing Combination Therapies to Enhance the Function of TGF-β Targeted Therapies
11:30 am Promoting Inflammation to Turn Tumors From ‘Cold’ to ‘Hot’ By Uniting TGF-β Directed Drugs & Checkpoint Inhibitors for More Effective Treatments
Synopsis
- Exploiting the immune system by combining TGF-β targets and checkpoint inhibitors to see positive patient response
- Heating the tumor up by encouraging inflammation for a strong immune response to therapy
- Overcoming immunotherapy resistance with TGF-β targeted therapy and checkpoint inhibitors to achieve clinical success
12:00 pm Utilizing Combination Therapies Targeting Diverse TGF-β-Dependent Anti- Fibrotic & Immunosuppressive Mechanisms in Oncology
Synopsis
- Refocusing from mono-directed TGF-β therapies to combination treatments for novel and effective anti-cancer therapies
- Exploring alternatives to checkpoint inhibitors for novel combination therapies using TGF-β targeted therapies
- Deep diving into ALK5 inhibitors in conjunction with autotaxin inhibitors to show clinical efficacy
New Data!
12:30 pm Overcoming Challenges of TGF-β Targeted Therapies by Selecting Suitable Combinations to Achieve Clinical Success
Synopsis
- Investigating different potential checkpoint inhibitors (SMAD, PD1) with TGF-β targetedtherapies for the most effective patient response
- Advancing to the next level by using proven combination TGF-β directed therapies to show clinical efficacy
- Employing a multi-pronged method to turn tumors from cold to hot
1:00 pm Networking Lunch
Unearthing Cutting-Edge Biomarkers & Monitoring the Patient Response to TGF-β Directed Therapies for Improved Patient Selection
2:00 pm Discovering New & Predictive Biomarkers for TGF-β to Improve Patient Predictive Response to Targeted Therapies
Synopsis
- Uncovering biomarkers for TGF-β targeted therapies to improve patient selection
- Finding TGF-β unique biomarkers that prove clinical viability
- Recognizing patient response by following TGF-β biomarkers to determine the most effective treatments
2:30 pm Roundtable Discussion: Examining the Patient Response During Trials to Prove the Clinical Benefit & Improve Patient Selection
Synopsis
- Scrutinizing patient response throughout treatment by following TGF-β biomarkers to improve later clinical selection
- Assessing the tumor microenvironment pre- and post-TGF-β targeted therapies to prove clinical efficacy
- Employing biomarkers to find clinical efficacy of TGF-β directed therapies
3:15 pm Afternoon Networking Break
Unlocking the Next Wave of TGF-β Directed Therapies Beyond Immuno-Oncology Towards Clinical Success
3:45 pm Investigating the Impact of Systemic & Targeted TGF-β Blockade on Fibrosis and Inflammation
Synopsis
- Comparing systemic TGF-β R1 inhibition to restricted targeting
- Uncovering the unique effects on inflammation observed in fibrotic models
- Highlighting lessons learned for fibrosis therapeutics and beyond
New Data!
4:15 pm Showcasing CUE-401: A Novel TGF-β/ IL-2 Fusion Protein for the Induction & Expansion of FOXP3+ Regulatory T Cells
Synopsis
- Exploring TGF-β and IL-2 as two key signals for the induction of regulatory T cell populations
- Developing CUE-401 as a novel TGF-β and IL-2 directed therapy for the selective expansion of regulatory T cells in vivo
- Unearthing the mechanism of action and the activity of CUE-401
New Data!
4:45 pm Spotlighting Immunotherapy for Autoimmune Diseases by Cell-Targeted Nanoparticles that Induce Local Production of TGF-β
Synopsis
- Discussing the mechanism of action of therapeutic nanoparticles that can generate TGF-β locally
- Determining the variety of disease indications for these cell-targeted nanoparticles
- Avoiding the possible toxicity of encapsulated TGF-β in nanoparticles by local generation of TGF-β